CTSO: CytoSorbents announces a Rights Offering for investors who hold or buy stock by tomorrow (12/13/24) which has the potential to substantially increase available liquidity.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
275 Views
CTSO: CytoSorbents reports 3rd quarter financial results. The company also submitted its Medical Device License (MDL) marketing application to Health Canada.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
93 Views
CTSO: CytoSorbents submits DrugSorb-ATR Marketing Application to the U.S. FDA. The company also provides Q3 2024 financial update.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
209 Views
CTSO: CytoSorbents reports solid 2nd quarter 2024 financial results which were above our expectations. The company remains on track to submit DrugSorb-ATR for regulatory approval in Q3 2024.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
191 Views
CTSO: CytoSorbents reports 1st quarter 2024 financial results and highlighted STAR-T trial data presentation at the AATS conference.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
167 Views
No more insights